Fig. 1 · Structure

Documents & Downloads

Zearalenone

Cat. No. A13740 CAS 17924-92-4
Zearalenone is a phytoestrogenic mycotoxin usually produced by Fusarium species, is shown to be a cytotoxic compound, but alos binds to the estrogen receptor (ER) (IC50 values are 166 and 240 nM for ERβ and ERα respectively) and was found to stimulate the transcriptional activity of both subtypes at concentrations between 1 - 10 nM.

In Stock

Publications for Zearalenone

1 publication citing this product

  1. Muthulakshmi S, .et al. , J Appl Toxicol, 2018, Nov;38(11):1388-1397 PMID: 29923290

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Zearalenone stimulated an estrogen-responsive reporter in MCF-7 cells, and ICI182,780 reduced this response. These findings support estrogen-receptor-mediated activity in this model; they do not establish receptor-isoform selectivity or a binding IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
HL-60 IC50 138.21 μM Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 27311894]
KB IC50 46.3 μM Cytotoxicity against human KB cells assessed as reduction in cell viability by resazurin microplate assay [PMID: 27311894]
MCF7 IC50 > 25 μM Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay [PMID: 21513293]
MCF7 IC50 104.72 μM Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay [PMID: 27311894]
NCI-H460 IC50 > 25 μM Cytotoxicity against human H460 cells after 72 hrs by MTS assay [PMID: 21513293]
SF-268 IC50 > 50 μM Cytotoxicity against human SF268 cells after 72 hrs by MTS assay [PMID: 21513293]
Vero IC50 40.58 μM Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by green fluorescent protein-based assay [PMID: 27311894]

Zearalenone Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Zearalenone from 2 published references. In vitro models include ER-positive human MCF-7 breast cancer cells.

Zearalenone In Vitro Studies

In MCF-7 cells, six-day zearalenone treatment increased cell number, with an author-reported plateau of approximately 80% of the estradiol effect. Zearalenone did not further alter the proliferative response to 10⁻⁹ M estradiol in the parallel combination experiment. [1]

Estrogen-responsive reporter activation and antagonist control

Cell-based study · ER-positive human MCF-7 breast cancer cells [1]

Zearalenone increased ERE-dependent reporter activity. ICI182,780 reduced the response, supporting involvement of estrogen receptors without establishing isoform selectivity or direct binding affinity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ERE-TK-luciferase activity normalized to the estradiol responseReported concentration-response Significant activation starting at 10⁻⁹ M (Results 3.1: p < 0.01); maximum within the tested range reported at 10⁻⁸ M.[1]
Response to 10⁻⁸ M zearalenone with or without 10⁻⁶ M ICI182,780Antagonist control ICI182,780 reduced zearalenone-stimulated luciferase activity; no bar-derived exact value assigned.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10⁻¹¹–10⁻⁶ M zearalenone concentration series; antagonist comparison: 10⁻⁸ M zearalenone ± 10⁻⁶ M ICI182,780.
Exposure duration
24 h for concentration-response experiments.
Method
Exposure of transfected, steroid-deprived MCF-7 cells.
Vehicle
Solvent control reported; solvent identity/concentration not specified in the selected assay methods.
Co-treatment
ICI182,780 cotreatment is a mechanistic control; estradiol is a separate positive control.
Reported limits
No EC50 or direct-binding measurement reported for this selected experiment. Figure 1D replication is not separately specified in the caption.
Methods and source locations

Compound reported in the paper: Zearalenone; Compound label in the paper: Zearalenone

Results apply to the reported zearalenone reagent and cellular model; no product-lot validation.

Methods 2.1–2.2, 2.8; Results 3.1; Figure 1A,D and caption

ERE-TK-luciferase activity normalized to the estradiol response: Luciferase reporter; CMV-β-galactosidase transfection control; solvent negative control and 10⁻⁹ M estradiol positive control. Figure 1A: means ± SEM of 3–4 independent experiments. — Methods 2.1–2.2, 2.8; Results 3.1; Figure 1A and caption

Response to 10⁻⁸ M zearalenone with or without 10⁻⁶ M ICI182,780: ERE reporter with antiestrogen cotreatment, compared with the corresponding treatment without antagonist. — Methods 2.2; Results 3.1; Figure 1D and caption

MCF-7 cell-number response with and without estradiol

Cell-based study · ER-positive human MCF-7 breast cancer cells [1]

Six-day zearalenone exposure increased cell number, reaching a plateau described by the authors as approximately 80% of the estradiol effect. Adding zearalenone did not alter proliferation driven by 10⁻⁹ M estradiol under these conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell number after zearalenone alone or in combination with estradiolRelative cell-number response Increase starting at 10⁻¹⁰ M; plateau approximately 80% of the 10⁻⁹ M estradiol effect (author-reported approximation). No added effect on estradiol-driven proliferation.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10⁻¹¹–10⁻⁶ M zearalenone, alone or with 10⁻⁹ M estradiol.
Exposure duration
6 days; retreatment on day 3.
Method
Cell-number determination after treatment of steroid/serum-deprived MCF-7 cells.
Vehicle
Untreated/control condition is shown; solvent identity and final concentration not specified in the selected proliferation methods.
Co-treatment
Parallel zearalenone plus estradiol series; effects are distinguished from zearalenone alone.
Reported limits
Cell number integrates cell division and death. No EC50 inferred from the curve; detailed solvent composition not retrieved from the selected methods.
Methods and source locations

Compound reported in the paper: Zearalenone; Compound label in the paper: Zearalenone

Results apply to the reported zearalenone reagent and cellular model; no product-lot validation.

Methods 2.1, 2.5, 2.8; Results 3.4; Figure 4A and caption

Cell number after zearalenone alone or in combination with estradiol: Automated cell counting; data expressed as percentage of cell number after estradiol treatment; means ± SEM of 3–4 independent experiments. — Methods 2.5, 2.8; Results 3.4; Figure 4A and caption

Zearalenone In Vivo Studies

In a 35-day dietary study in weaned gilts, zearalenone increased uterine ERα, ERβ and progesterone-receptor mRNA and protein expression. The findings describe receptor-expression responses in this animal model and do not by themselves demonstrate that receptor activation caused uterine growth. [2]

Uterine receptor expression after dietary zearalenone in weaned gilts

Animal study · Forty weaned female Duroc × Landrace × Large White pigs; 10 animals randomized per dietary group. [2]

Dietary zearalenone was associated with increased uterine ERα, ERβ and progesterone-receptor transcript and protein expression. The study establishes an expression response, without receptor blockade or proof that receptor activation caused uterine growth.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative uterine ERα, ERβ and progesterone receptor mRNA expressionDirection and reported significance Positive linear responses to dietary ZEA (p < 0.05, Results 2.4); expression at 1.0 and 1.5 mg/kg feed exceeded control and 0.5 mg/kg feed. ERα also increased at 0.5 mg/kg feed versus control.[2]
Relative uterine ERα, ERβ and progesterone-receptor protein expressionDirection and reported significance Positive linear responses (p < 0.05, Results 2.5); all ZEA dietary groups exceeded control.[2]

Conditions shared by the study groups

Route
Oral, in feed.
Frequency
Dietary exposure throughout the treatment period.
Treatment course
35 days.
Vehicle
Basal feed.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
ZEA0.5
0.5 mg ZEA/kg feed (nominal).
Basal diet with 0 mg added ZEA/kg feed; 10 allocated animals.Uterine ERα, ERβ and progesterone-receptor protein expression exceeded control (p < 0.05); transcript differences depend on receptor and dose as specified in meas_uterine_transcripts.[2]
ZEA1.0
1.0 mg ZEA/kg feed (nominal).
Basal diet with 0 mg added ZEA/kg feed; 10 allocated animals.Uterine ERα, ERβ and progesterone-receptor protein expression exceeded control (p < 0.05); transcript differences depend on receptor and dose as specified in meas_uterine_transcripts.[2]
ZEA1.5
1.5 mg ZEA/kg feed (nominal).
Basal diet with 0 mg added ZEA/kg feed; 10 allocated animals.Uterine ERα, ERβ and progesterone-receptor protein expression exceeded control (p < 0.05); transcript differences depend on receptor and dose as specified in meas_uterine_transcripts.[2]
ZEA0.5
Model: Weaned female pigs; 10 allocated animals in this dietary group.
Reported limits: Figure 4 does not state an assay-specific biological n or define its error bars.
ZEA1.0
Model: Weaned female pigs; 10 allocated animals in this dietary group.
Reported limits: Figure 4 does not state an assay-specific biological n or define its error bars.
ZEA1.5
Model: Weaned female pigs; 10 allocated animals in this dietary group.
Reported limits: Figure 4 does not state an assay-specific biological n or define its error bars.
Methods and source locations

Compound reported in the paper: Zearalenone; Compound label in the paper: ZEA

Dietary zearalenone results in weaned female pigs; no inference of equivalent human exposure or validation of an Adooq lot.

Results 2.4–2.5; Figure 4B,C and caption; Methods 5.1–5.2, 5.5, 5.8–5.10

Relative uterine ERα, ERβ and progesterone receptor mRNA expression: Quantitative RT-PCR; 10 pigs per treatment; technical triplicates described. No exact fold changes extracted. — Results 2.4; Figure 4B and caption; Methods 5.2, 5.5, 5.8, 5.10

Relative uterine ERα, ERβ and progesterone-receptor protein expression: Western blot with GAPDH control; no exact densitometric values extracted. — Results 2.5; Figure 4C and caption; Methods 5.2, 5.5, 5.9–5.10

ZEA0.5 · Results 2.4–2.5; Figure 4B,C; Methods 5.2, 5.8–5.10

ZEA1.0 · Results 2.4–2.5; Figure 4B,C; Methods 5.2, 5.8–5.10

ZEA1.5 · Results 2.4–2.5; Figure 4B,C; Methods 5.2, 5.8–5.10

Specifications

Manufacturer Adooq Bioscience
CAS Number 17924-92-4
Formula C18H22O5
Molecular Weight 318.36
SMILES
C[C@H]1CCCC(=O)CCC/C=C/C2=CC(=CC(=C2C(=O)O1)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 56 mg/mL (175.9 mM)
Water Insoluble
Ethanol 56 mg/mL (175.9 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Zearalenone Research References

  1. [1] Lecomte S, Demay F, Pham TH, et al. Deciphering the Molecular Mechanisms Sustaining the Estrogenic Activity of the Two Major Dietary Compounds Zearalenone and Apigenin in ER-Positive Breast Cancer Cell Lines Nutrients (2019). PMID: 30678243 DOI: 10.3390/nu11020237 Source material
  2. [2] Song T, Zhou X, Ma X, et al. Zearalenone Promotes Uterine Development of Weaned Gilts by Interfering with Serum Hormones and Up-Regulating Expression of Estrogen and Progesterone Receptors Toxins (2022). PMID: 36355982 DOI: 10.3390/toxins14110732 Source material

Publications

1 publication citing this product

  1. Muthulakshmi S, .et al. , J Appl Toxicol, 2018, Nov;38(11):1388-1397 PMID: 29923290

Added to your cart

View Cart Checkout
Loading...